CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 50 enrolled
Drug / intervention
Devers Drop Device (D3) appdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03506568
NCT03506568N/ACompleted
CompareCT.gov

A Universal Eye Drop Adherence Monitor to Measure and Improve Adherence to Ocular Medications

Universal Adherence LLC·interventional·Posted Apr 24, 2018·Updated Feb 21, 2023

In Brief

A clinical study evaluating Devers Drop Device (D3) app for Medication Adherence and Glaucoma. Completed, enrolled 50 participants across 1 site.

Detailed Summary

Glaucoma is the second leading cause of visual impairment worldwide. Eye drop medications reduce vision loss from glaucoma by at least 60%, but eye drops must be taken every day to be effective. However, adherence to eye drop treatment is poor with only 50% of patients regularly taking their prescribed eye drops. The investigators are developing the Devers Drop Device (D3) eye drop monitor to accurately measure eye drop cap removal and to improve eye drop-taking behavior. The investigators will test eye drop adherence with the D3 device in a randomized, prospective clinical trial.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMedication Adherence, Glaucoma
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), Oregon State University, National Eye Institute (NEI)

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedApr 24, 2018
Enrollment StartOct 2, 2020
Primary CompletionJun 4, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 8.2 years ago

Interventions

Devers Drop Device (D3) appdevice

A universal eye drop cap monitor that accurately measures and improves eye drop-taking behavior.